Cargando…

Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall

Prolymphocytic transformation is a concept usually applied in the context of chronic lymphocytic leukemia/small lymphocytic lymphoma to describe the presence of a high percentage of prolymphocytes in peripheral blood (usually more than 55%). Prolymphocytic transformation has also been reported in ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Algashaamy, Khaled, Tan, Yaohong, Mackrides, Nicolas, Alencar, Alvaro, Peng, Jing-Hong, Rosenblatt, Joseph, Alderuccio, Juan P, Lossos, Izidore S., Vega, Francisco, Chapman, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180998/
https://www.ncbi.nlm.nih.gov/pubmed/30363761
http://dx.doi.org/10.1155/2018/5761953
_version_ 1783362329282347008
author Algashaamy, Khaled
Tan, Yaohong
Mackrides, Nicolas
Alencar, Alvaro
Peng, Jing-Hong
Rosenblatt, Joseph
Alderuccio, Juan P
Lossos, Izidore S.
Vega, Francisco
Chapman, Jennifer
author_facet Algashaamy, Khaled
Tan, Yaohong
Mackrides, Nicolas
Alencar, Alvaro
Peng, Jing-Hong
Rosenblatt, Joseph
Alderuccio, Juan P
Lossos, Izidore S.
Vega, Francisco
Chapman, Jennifer
author_sort Algashaamy, Khaled
collection PubMed
description Prolymphocytic transformation is a concept usually applied in the context of chronic lymphocytic leukemia/small lymphocytic lymphoma to describe the presence of a high percentage of prolymphocytes in peripheral blood (usually more than 55%). Prolymphocytic transformation has also been reported in mantle cell lymphoma (MCL) but only rarely in splenic marginal zone lymphoma (SMZL). We present two splenic B-cell lymphomas presenting in the leukemic phase and with increased prolymphocytes, both classified as SMZL with prolymphocytic transformation. One case clinically simulated B-prolymphocytic leukemia (B-PLL). Both lymphomas were very unusual because the tumor cells diffusely and strongly expressed cyclin D1 despite lacking the t(11; 14)(q13; q32) as detected by several approaches including next-generation sequencing, fluorescence in situ hybridization using CCND1 break apart probe and fusion probes for t(11; 14)(q13; q32), and conventional karyotyping. These cases therefore simulated prolymphocytic variants of MCL. The incidence of this phenomenon is unknown, and awareness of this potential alternate protein expression pattern is important in order to avoid diagnostic errors.
format Online
Article
Text
id pubmed-6180998
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-61809982018-10-24 Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall Algashaamy, Khaled Tan, Yaohong Mackrides, Nicolas Alencar, Alvaro Peng, Jing-Hong Rosenblatt, Joseph Alderuccio, Juan P Lossos, Izidore S. Vega, Francisco Chapman, Jennifer Case Rep Hematol Case Report Prolymphocytic transformation is a concept usually applied in the context of chronic lymphocytic leukemia/small lymphocytic lymphoma to describe the presence of a high percentage of prolymphocytes in peripheral blood (usually more than 55%). Prolymphocytic transformation has also been reported in mantle cell lymphoma (MCL) but only rarely in splenic marginal zone lymphoma (SMZL). We present two splenic B-cell lymphomas presenting in the leukemic phase and with increased prolymphocytes, both classified as SMZL with prolymphocytic transformation. One case clinically simulated B-prolymphocytic leukemia (B-PLL). Both lymphomas were very unusual because the tumor cells diffusely and strongly expressed cyclin D1 despite lacking the t(11; 14)(q13; q32) as detected by several approaches including next-generation sequencing, fluorescence in situ hybridization using CCND1 break apart probe and fusion probes for t(11; 14)(q13; q32), and conventional karyotyping. These cases therefore simulated prolymphocytic variants of MCL. The incidence of this phenomenon is unknown, and awareness of this potential alternate protein expression pattern is important in order to avoid diagnostic errors. Hindawi 2018-09-27 /pmc/articles/PMC6180998/ /pubmed/30363761 http://dx.doi.org/10.1155/2018/5761953 Text en Copyright © 2018 Khaled Algashaamy et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Algashaamy, Khaled
Tan, Yaohong
Mackrides, Nicolas
Alencar, Alvaro
Peng, Jing-Hong
Rosenblatt, Joseph
Alderuccio, Juan P
Lossos, Izidore S.
Vega, Francisco
Chapman, Jennifer
Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall
title Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall
title_full Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall
title_fullStr Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall
title_full_unstemmed Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall
title_short Splenic B-Cell Lymphomas with Diffuse Cyclin D1 Protein Expression and Increased Prolymphocytic Cells: A Previously Unrecognized Diagnostic Pitfall
title_sort splenic b-cell lymphomas with diffuse cyclin d1 protein expression and increased prolymphocytic cells: a previously unrecognized diagnostic pitfall
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180998/
https://www.ncbi.nlm.nih.gov/pubmed/30363761
http://dx.doi.org/10.1155/2018/5761953
work_keys_str_mv AT algashaamykhaled splenicbcelllymphomaswithdiffusecyclind1proteinexpressionandincreasedprolymphocyticcellsapreviouslyunrecognizeddiagnosticpitfall
AT tanyaohong splenicbcelllymphomaswithdiffusecyclind1proteinexpressionandincreasedprolymphocyticcellsapreviouslyunrecognizeddiagnosticpitfall
AT mackridesnicolas splenicbcelllymphomaswithdiffusecyclind1proteinexpressionandincreasedprolymphocyticcellsapreviouslyunrecognizeddiagnosticpitfall
AT alencaralvaro splenicbcelllymphomaswithdiffusecyclind1proteinexpressionandincreasedprolymphocyticcellsapreviouslyunrecognizeddiagnosticpitfall
AT pengjinghong splenicbcelllymphomaswithdiffusecyclind1proteinexpressionandincreasedprolymphocyticcellsapreviouslyunrecognizeddiagnosticpitfall
AT rosenblattjoseph splenicbcelllymphomaswithdiffusecyclind1proteinexpressionandincreasedprolymphocyticcellsapreviouslyunrecognizeddiagnosticpitfall
AT alderucciojuanp splenicbcelllymphomaswithdiffusecyclind1proteinexpressionandincreasedprolymphocyticcellsapreviouslyunrecognizeddiagnosticpitfall
AT lossosizidores splenicbcelllymphomaswithdiffusecyclind1proteinexpressionandincreasedprolymphocyticcellsapreviouslyunrecognizeddiagnosticpitfall
AT vegafrancisco splenicbcelllymphomaswithdiffusecyclind1proteinexpressionandincreasedprolymphocyticcellsapreviouslyunrecognizeddiagnosticpitfall
AT chapmanjennifer splenicbcelllymphomaswithdiffusecyclind1proteinexpressionandincreasedprolymphocyticcellsapreviouslyunrecognizeddiagnosticpitfall